Cefpodoxime Other names: Cefpodoxime Proxetil

Chemical formula: C₁₅H₁₇N₅O₆S₂  Molecular mass: 427.455 g/mol  PubChem compound: 6335986

Therapeutic indications

Cefpodoxime is indicated for:

Infections in the ear, nose and throat area

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

  • Tonsillitis, pharyngitis
  • Acute otitis media

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute bronchitis, bacterial pneumonia

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Acute bronchitis
Acute exacerbation of chronic bronchitis
Bacterial pneumonia
and additionally at least one of
Cefpodoxime susceptible species
Cefpodoxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Uncomplicated gonorrhea in men and women, uncomplicated rectal gonococcal infections in women

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Infections of skin and soft tissues

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Infective dermatological disorders
Soft tissue infection
and additionally at least one of
Cefpodoxime susceptible species
Cefpodoxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute maxillary sinusitis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Uncomplicated urinary tract infection

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Cystitis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Cefpodoxime is contraindicated in the following cases:

Hypersensitivity to cephalosporin, hypersensitivity to penicillins

at least one of
Cephalosporin allergy
Allergy to penicillin

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL) 2019: CEFPODOXIME PROXETIL Granule, for suspension
Summary of Product Characteristics (SPC) : CEFPODOXIME LUPIN Powder for oral suspension
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈